Retrospective public health impact of a quadrivalent influenza vaccine in the United States

Influenza and other Respiratory Viruses

Volumn 9, Issue S1, 2015, Pages 39-46

  Crépey, pascal ^a,b   de Boer, Pieter T ^c   Postma, Maarten J ^c,d   Pitman, Richard ^e  

^a Sorbonne Paris Cite   (France)

^b Aix Marseille University IRD 190 Inserm 1207   (France)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e ICON CLINICAL RESEARCH   (United States)

Author keywords

Dynamic model; Influenza; Quadrivalent influenza vaccine; Trivalent influenza vaccine; Vaccine effectiveness; Vaccines

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; POPULATION DYNAMICS; PRIORITY JOURNAL; PUBLIC HEALTH; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; UNITED STATES; ADOLESCENT; AGE; BIOLOGICAL MODEL; CHEMISTRY; CHILD; FEMALE; GENETICS; IMMUNOLOGY; INFANT; INFLUENZA B VIRUS; INFLUENZA, HUMAN; LICENSING; MALE; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CROSS PROTECTION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LICENSURE; MALE; MIDDLE AGED; MODELS, IMMUNOLOGICAL; PUBLIC HEALTH; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84938817551     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12318     Document Type: Article

References (17)

1. Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines 2013; 12:1085-1094.
2. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine 2012; 31:49-57.
3. Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013; 31:770-776.
4. Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. Pediatr Infect Dis J 2014; 33:630-636.
5. Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 2013; 31:5572-5578.
6. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30:1993-1998.
7. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012; 30:7443-7446.
8. Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS ONE 2014; 9:e98437.
9. Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccine Immunother 2014; 10:1171-1180.
10. Tricco AC, Chit A, Soobiah C et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med 2013; 11:153.
11. Mossong J, Hens N, Jit M et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008; 5:e74.
12. Zagheni E, Billari FC, Manfredi P, Melegaro A, Mossong J, Edmunds WJ. Using time-use data to parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol 2008; 168:1082-1090.
13. Nelder JA, Mead R. A simplex method for function minimization. Comput J 1965; 7:308-313.
14. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2014.
15. Vynnycky E, White R. An Introduction to Infectious Disease Modelling. New York: Oxford University Press, 2010.
16. Carrat F, Vergu E, Ferguson NM et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008; 167:775-785.
17. Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine 2008; 26:5321-5330.